A Retrospective Study of the Correlation of in Vitro Chemosensitivity Using ATP-TCA with Patient Clinical Outcomes in Acute Myeloid Leukemia

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2019 Oct 27

PMID 31654111

Citations 4

Authors

Fan Xia

Sheng Ma

Yicong Bian

Di Yu

Wenxia Ma

Miao Miao

Chenrong Huang

Liyan Miao

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the predictive value of the in vitro chemosensitivity using ATP-TCA method to compare the clinical efficacy of patients with AML.

Methods: Bone marrow or peripheral blood samples were collected from 65 patients with AML, and the in vitro chemosensitivity of four drugs (cytarabine/idarubicin/decitabine/aclacinomycin) was measured by an ATP-tumor chemosensitivity assay.

Results: Aclacinomycin and cytarabine had the highest chemosensitivity rates (66.7%, 8/12 and 58.5%, 38/65, respectively), while idarubicin and decitabine had rates of 6.5% (3/46) and 0% (0/35), respectively. Complete remission (CR) was achieved in 66.2% (43/65) of patients, and there was a statistically significant correlation between CR and in vitro chemosensitivity for cytarabine (47.7% vs 18.5%, p = 0.002), but not for the anthracyclines (p = 0.950). In addition, three other factors significantly correlated with CR: disease status (p = 0.005), FLT3-ITD/TKD mutation (p = 0.003) and chemotherapy regimens (p = 0.004). Furthermore, multiple logistic regression analysis revealed that the sensitivity of cytarabine was one of the significant risk factors for CR [hazard ratio (HR) = 5.52; 95% confidence interval (CI) = 1.47-20.70; p = 0.011].

Conclusions: The in vitro chemosensitivity as tested by ATP-TCA demonstrated a significant correlation with CR for chemotherapy and can be a useful tool to optimize personalized treatments for patients with AML.

Citing Articles

Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin.

Kirilin E, Fetisov T, Moiseeva N, Lesovaya E, Laletina L, Makhmudova L Cancers (Basel). 2022; 14(7).

PMID: 35406568 PMC: 8997914. DOI: 10.3390/cancers14071796.

Analysis of Multiple Drug Resistance Mechanism in Different Types of Soft Tissue Sarcomas: Assessment of the Expression of ABC-Transporters, MVP, YB-1, and Analysis of Their Correlation with Chemosensitivity of Cancer Cells.

Moiseeva N, Laletina L, Fetisov T, Makhmudova L, Manikaylo A, Fomina L Int J Mol Sci. 2022; 23(6).

PMID: 35328603 PMC: 8951302. DOI: 10.3390/ijms23063183.

Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy.

Zhang Y, Ji M, Zhao J, Wang H, Wang C, Li W Front Oncol. 2022; 11:793773.

PMID: 35071002 PMC: 8767104. DOI: 10.3389/fonc.2021.793773.

Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients.

Ulukaya E, Karakas D, Dimas K Medicina (Kaunas). 2021; 57(6).

PMID: 34205407 PMC: 8234301. DOI: 10.3390/medicina57060636.

References

Bosserman L, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S . The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care. Cancer Res. 2012; 72(16):3901-5. DOI: 10.1158/0008-5472.CAN-12-0681. View

Chen Z, Zhang S, Ma S, Li C, Xu C, Shen Y . Evaluation of the in vitro Chemosensitivity and Correlation with Clinical Outcomes in Lung Cancer using the ATP-TCA. Anticancer Agents Med Chem. 2017; 18(1):139-145. DOI: 10.2174/1871520617666170419123713. View

Zhang J, Li H . Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay. Oncol Lett. 2015; 9(5):2374-2380. PMC: 4467356. DOI: 10.3892/ol.2015.3056. View

Zhang Y, Zhao Q, Jiang Y, Yuan Z, Yang L . [ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014; 38(12):1223-7. DOI: 10.3969/j.issn.1672-7347.2013.12.004. View

Ling Z, Qi C, Lu X, Qian L, Gu L, Zheng Z . Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay. Acta Pharmacol Sin. 2012; 33(3):401-6. PMC: 4077137. DOI: 10.1038/aps.2011.195. View

Fehm T, Zwirner M, Wallwiener D, Seeger H, Neubauer H . Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer. 2012; 12:308. PMC: 3416722. DOI: 10.1186/1471-2407-12-308. View

Klumper E, Pieters R, Kaspers G, Huismans D, Loonen A, Rottier M . In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia. 1995; 9(11):1864-9. View

Strickland S, Raptis A, Hallquist A, Rutledge J, Chernick M, Perree M . Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia. Leuk Lymphoma. 2012; 54(3):528-34. DOI: 10.3109/10428194.2012.722217. View

Cheson B, Bennett J, Kopecky K, Buchner T, Willman C, Estey E . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-9. DOI: 10.1200/JCO.2003.04.036. View

10.

Burnett A, Wetzler M, Lowenberg B . Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011; 29(5):487-94. DOI: 10.1200/JCO.2010.30.1820. View

11.

Kadia T, Ravandi F, Cortes J, Kantarjian H . Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. JAMA Oncol. 2015; 1(6):820-8. DOI: 10.1001/jamaoncol.2015.0617. View

12.

Kadia T, Ravandi F, OBrien S, Cortes J, Kantarjian H . Progress in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014; 15(3):139-51. PMC: 4344862. DOI: 10.1016/j.clml.2014.08.006. View

13.

Luskin M, Lee J, Fernandez H, Abdel-Wahab O, Bennett J, Ketterling R . Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016; 127(12):1551-8. PMC: 4807422. DOI: 10.1182/blood-2015-07-657403. View

14.

Daneshbod Y, Kohan L, Taghadosi V, Weinberg O, Arber D . Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia. Curr Treat Options Oncol. 2019; 20(2):15. DOI: 10.1007/s11864-019-0612-y. View

15.

Smith C, Lin K, Stecula A, Sali A, Shah N . FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia. 2015; 29(12):2390-2. PMC: 4675689. DOI: 10.1038/leu.2015.165. View

16.

Smith R, Pontiggia L, Waterman C, Lichtenwalner M, Wasserman J . Comparison of motility, recovery, and methyl-thiazolyl-tetrazolium reduction assays for use in screening plant products for anthelmintic activity. Parasitol Res. 2009; 105(5):1339-43. DOI: 10.1007/s00436-009-1560-4. View

17.

Irisawa C, Aikawa K, Ogihara M, Hashimoto T, Yamaguchi O, Shiraiwa Y . [Clinical results of prophylactic intravesical chemotherapy on superficial bladder cancer using the dye exclusion assay]. Nihon Hinyokika Gakkai Zasshi. 1992; 83(11):1828-34. DOI: 10.5980/jpnjurol1989.83.1828. View

18.

Glaysher S, Cree I . Cell sensitivity assays: the ATP-based tumor chemosensitivity assay. Methods Mol Biol. 2011; 731:247-57. DOI: 10.1007/978-1-61779-080-5_21. View

19.

Oki Y, Aoki E, Issa J . Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2006; 61(2):140-52. DOI: 10.1016/j.critrevonc.2006.07.010. View

20.

Estey E, Dohner H . Acute myeloid leukaemia. Lancet. 2006; 368(9550):1894-907. DOI: 10.1016/S0140-6736(06)69780-8. View